Trials / Terminated
TerminatedNCT02266147
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Dynavax Technologies Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SD-101 | |
| RADIATION | Radiation therapy |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2014-10-16
- Last updated
- 2020-09-04
- Results posted
- 2020-09-04
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02266147. Inclusion in this directory is not an endorsement.